Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
76.64
Dollar change
+0.90
Percentage change
1.19
%
IndexRUT P/E- EPS (ttm)-2.16 Insider Own51.67% Shs Outstand58.63M Perf Week-3.85%
Market Cap4.91B Forward P/E- EPS next Y-3.41 Insider Trans-1.31% Shs Float30.96M Perf Month-13.88%
Income-126.22M PEG- EPS next Q-0.65 Inst Own61.15% Short Float22.78% Perf Quarter3.15%
Sales0.00M P/S- EPS this Y-34.42% Inst Trans-1.04% Short Ratio18.51 Perf Half Y82.13%
Book/sh10.94 P/B7.01 EPS next Y-16.90% ROA-20.78% Short Interest7.05M Perf Year173.03%
Cash/sh11.24 P/C6.82 EPS next 5Y- ROE-21.70% 52W Range23.09 - 89.39 Perf YTD4.14%
Dividend Est.- P/FCF- EPS past 5Y-72.54% ROI-18.02% 52W High-14.26% Beta1.32
Dividend TTM- Quick Ratio22.83 Sales past 5Y0.00% Gross Margin- 52W Low231.85% ATR (14)3.50
Dividend Ex-Date- Current Ratio22.83 EPS Y/Y TTM-31.75% Oper. Margin0.00% RSI (14)40.85 Volatility3.63% 4.26%
Employees92 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.33 Target Price96.50
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-26.40% Payout- Rel Volume0.81 Prev Close75.74
Sales Surprise- EPS Surprise-2.99% Sales Q/Q- EarningsFeb 27 BMO Avg Volume380.94K Price76.64
SMA20-6.83% SMA50-5.14% SMA20027.29% Trades Volume309,844 Change1.19%
Date Action Analyst Rating Change Price Target Change
Feb-28-24Resumed Guggenheim Buy $99
Feb-23-24Initiated Robert W. Baird Outperform $105
Sep-27-23Initiated Stifel Buy $65
Aug-08-23Initiated SVB Securities Market Perform $42
Jul-24-23Initiated Guggenheim Buy $56
Jan-18-23Initiated Wedbush Outperform $39
Jun-24-22Initiated BMO Capital Markets Outperform $28
Mar-25-24 07:01PM
Mar-19-24 07:01PM
Mar-05-24 04:52PM
Feb-29-24 04:32AM
Feb-27-24 06:30AM
06:15AM Loading…
06:15AM
Feb-22-24 04:00AM
Feb-12-24 06:30AM
Feb-01-24 06:30AM
Jan-08-24 06:30AM
Dec-22-23 03:01PM
Dec-21-23 01:01PM
06:30AM
Nov-14-23 07:15PM
06:30AM
07:02AM Loading…
Nov-04-23 07:02AM
Nov-01-23 06:30AM
Oct-23-23 02:50AM
Oct-17-23 06:27PM
Oct-16-23 09:55PM
07:30AM
Oct-13-23 06:30AM
Oct-07-23 01:00AM
Oct-05-23 07:13PM
10:29AM
01:01AM
Oct-04-23 04:13PM
12:21PM
Sep-18-23 06:30AM
Sep-05-23 06:30AM
06:30AM Loading…
Aug-31-23 06:30AM
Aug-17-23 06:40AM
Aug-10-23 06:30AM
Aug-08-23 10:02AM
Aug-01-23 06:30AM
Jul-21-23 08:50AM
Jun-07-23 08:50AM
May-24-23 06:30AM
May-11-23 06:30AM
Apr-19-23 06:30AM
Apr-18-23 09:00AM
Apr-02-23 10:56AM
Mar-23-23 06:30AM
Mar-16-23 06:30AM
Mar-14-23 05:59PM
Mar-01-23 06:30AM
Jan-04-23 06:30AM
Jan-02-23 09:40AM
Dec-13-22 10:15AM
Dec-12-22 03:44PM
Dec-02-22 08:50AM
Nov-17-22 12:00PM
Nov-10-22 06:30AM
Nov-03-22 08:13PM
Oct-31-22 09:14PM
07:15AM
Oct-28-22 04:18PM
04:06PM
11:10AM
12:01AM
Oct-26-22 06:30AM
Oct-23-22 09:26AM
Oct-17-22 06:30AM
Oct-06-22 06:30AM
Sep-20-22 10:16AM
Sep-07-22 06:30AM
Sep-01-22 06:30AM
Aug-10-22 06:30AM
Aug-05-22 06:30AM
Aug-03-22 06:30AM
Jul-20-22 06:30AM
Jul-13-22 06:30AM
Jul-01-22 10:52AM
Jun-21-22 06:30AM
Jun-02-22 06:38AM
May-16-22 09:10AM
May-12-22 06:30AM
Apr-11-22 07:21AM
Apr-08-22 01:15PM
Apr-07-22 06:30AM
Mar-31-22 06:30AM
Mar-29-22 06:30AM
Mar-08-22 05:38PM
Mar-02-22 06:30AM
Feb-03-22 06:30AM
Jan-07-22 06:30AM
Jan-04-22 06:30AM
Nov-10-21 06:30AM
Oct-29-21 09:55AM
Oct-07-21 09:21AM
Sep-08-21 06:30AM
Aug-06-21 06:26PM
Aug-02-21 05:39PM
Jul-28-21 11:22PM
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shair MatthewDirectorMar 25 '24Sale76.7737,5002,878,9821,687,198Mar 27 04:55 PM
Shair MatthewDirectorMar 25 '24Sale76.772,000153,546238,522Mar 27 04:55 PM
Noci DarleneChief Development OfficerMar 22 '24Option Exercise7.7420,000154,80053,300Mar 25 04:49 PM
Noci DarleneChief Development OfficerMar 22 '24Sale77.5120,0001,550,22933,300Mar 25 04:49 PM
Conley EmilyDirectorMar 15 '24Option Exercise9.3613,333124,79713,341Mar 19 04:46 PM
Conley EmilyDirectorMar 15 '24Sale80.9213,3331,078,8838Mar 19 04:46 PM
Shair MatthewDirectorDec 28 '23Sale75.4648,5483,663,4921,724,698Dec 28 05:09 PM
Shair MatthewDirectorDec 27 '23Sale75.171,00075,1701,773,246Dec 28 05:09 PM
Shair MatthewDirectorDec 26 '23Sale75.1269,6025,228,3461,774,246Dec 28 05:09 PM
Miller Deborah AnnChief Legal OfficerDec 19 '23Option Exercise18.935,00094,6505,000Dec 20 04:54 PM
Miller Deborah AnnChief Legal OfficerDec 19 '23Sale75.005,000375,0000Dec 20 04:54 PM
Miller Deborah AnnChief Legal OfficerDec 18 '23Option Exercise27.8533,046920,33133,046Dec 20 04:54 PM
Noci DarleneChief Development OfficerDec 18 '23Option Exercise4.7040,000188,13940,000Dec 20 04:56 PM
Protopapas AnnaDirectorDec 18 '23Option Exercise9.365,00046,8005,000Dec 20 04:58 PM
Balcom AlexandraChief Financial OfficerDec 18 '23Option Exercise1.0830,00032,40030,000Dec 20 04:51 PM
Noci DarleneChief Development OfficerDec 18 '23Sale75.8240,0003,032,8000Dec 20 04:56 PM
Miller Deborah AnnChief Legal OfficerDec 18 '23Sale75.8233,0462,505,5480Dec 20 04:54 PM
Balcom AlexandraChief Financial OfficerDec 18 '23Sale75.8230,0002,274,6000Dec 20 04:51 PM
Protopapas AnnaDirectorDec 18 '23Sale75.675,000378,3500Dec 20 04:58 PM
Shair MatthewDirectorNov 28 '23Sale61.899,150566,3031,843,848Nov 30 04:47 PM
Noci DarleneChief Development OfficerNov 01 '23Option Exercise1.083,0003,2403,000Nov 03 04:43 PM
Noci DarleneChief Development OfficerNov 01 '23Sale52.663,000157,9750Nov 03 04:43 PM
Shair MatthewDirectorOct 24 '23Sale50.7091,7004,648,8721,852,998Oct 26 04:47 PM
Noci DarleneChief Development OfficerOct 04 '23Option Exercise5.5620,000111,15020,000Oct 06 04:56 PM
Turner Christopher DurantChief Medical OfficerOct 04 '23Option Exercise6.897,99555,08622,508Oct 06 04:58 PM
Noci DarleneChief Development OfficerOct 04 '23Sale55.9920,0001,119,7020Oct 06 04:56 PM
Turner Christopher DurantChief Medical OfficerOct 04 '23Sale54.047,995432,03114,513Oct 06 04:58 PM
Noci DarleneChief Development OfficerOct 02 '23Option Exercise1.083,0003,2403,000Oct 04 04:24 PM
Noci DarleneChief Development OfficerOct 02 '23Sale45.883,000137,6490Oct 04 04:24 PM
Miller Deborah AnnChief Legal OfficerSep 15 '23Option Exercise6.892,00013,7802,000Sep 19 04:45 PM
Miller Deborah AnnChief Legal OfficerSep 15 '23Sale47.642,00095,2830Sep 19 04:45 PM
Noci DarleneChief Development OfficerSep 01 '23Option Exercise1.083,0003,2403,000Sep 06 04:36 PM
Noci DarleneChief Development OfficerSep 01 '23Sale46.563,000139,6920Sep 06 04:36 PM
Miller Deborah AnnChief Legal OfficerAug 15 '23Option Exercise6.892,00013,7802,000Aug 17 04:29 PM
Miller Deborah AnnChief Legal OfficerAug 15 '23Sale42.652,00085,3100Aug 17 04:29 PM
Noci DarleneChief Development OfficerAug 01 '23Option Exercise1.083,0003,2403,000Aug 01 05:26 PM
Noci DarleneChief Development OfficerAug 01 '23Sale49.953,000149,8440Aug 01 05:26 PM
Balcom AlexandraChief Financial OfficerJul 31 '23Option Exercise1.0825,00027,00025,000Aug 01 04:16 PM
Balcom AlexandraChief Financial OfficerJul 31 '23Sale48.9925,0001,224,7960Aug 01 04:16 PM
Miller Deborah AnnChief Legal OfficerJul 28 '23Option Exercise6.896,50044,7856,500Aug 01 04:13 PM
Turner Christopher DurantChief Medical OfficerJul 28 '23Option Exercise6.892,66518,36217,178Jul 28 04:51 PM
Miller Deborah AnnChief Legal OfficerJul 28 '23Sale48.526,500315,3800Aug 01 04:13 PM
Turner Christopher DurantChief Medical OfficerJul 28 '23Sale48.932,665130,39814,513Jul 28 04:51 PM
Turner Christopher DurantChief Medical OfficerJul 26 '23Option Exercise6.892,36516,29516,878Jul 28 04:51 PM
Turner Christopher DurantChief Medical OfficerJul 26 '23Sale46.852,365110,80014,513Jul 28 04:51 PM
Turner Christopher DurantChief Medical OfficerJul 24 '23Option Exercise6.892001,37814,713Jul 24 04:54 PM
Turner Christopher DurantChief Medical OfficerJul 24 '23Sale46.822009,36414,513Jul 24 04:54 PM
Noci DarleneChief Development OfficerJul 20 '23Option Exercise1.0810,94111,81610,941Jul 21 04:47 PM
Turner Christopher DurantChief Medical OfficerJul 20 '23Option Exercise6.8910068914,613Jul 24 04:54 PM
Noci DarleneChief Development OfficerJul 20 '23Sale45.1710,941494,2050Jul 21 04:47 PM
Turner Christopher DurantChief Medical OfficerJul 20 '23Sale46.801004,68014,513Jul 24 04:54 PM
Noci DarleneChief Development OfficerJul 19 '23Option Exercise1.084,5594,9244,559Jul 21 04:47 PM
Noci DarleneChief Development OfficerJul 19 '23Sale45.044,559205,3370Jul 21 04:47 PM
Miller Deborah AnnChief Legal OfficerJul 17 '23Option Exercise6.892,00013,7802,000Jul 19 04:43 PM
Miller Deborah AnnChief Legal OfficerJul 17 '23Sale43.062,00086,1230Jul 19 04:43 PM
Noci DarleneChief Development OfficerJul 03 '23Option Exercise1.083,0003,2403,000Jul 06 04:51 PM
Noci DarleneChief Development OfficerJul 03 '23Sale41.483,000124,4270Jul 06 04:51 PM
Noci DarleneChief Development OfficerJun 16 '23Option Exercise1.082,9003,1322,900Jun 20 04:45 PM
Noci DarleneChief Development OfficerJun 16 '23Sale45.192,900131,0510Jun 20 04:45 PM
Miller Deborah AnnChief Legal OfficerJun 15 '23Option Exercise6.892,00013,7802,000Jun 20 04:42 PM
Noci DarleneChief Development OfficerJun 15 '23Option Exercise1.081,0001,0801,000Jun 20 04:45 PM
Miller Deborah AnnChief Legal OfficerJun 15 '23Sale44.282,00088,5650Jun 20 04:42 PM
Noci DarleneChief Development OfficerJun 15 '23Sale45.071,00045,0700Jun 20 04:45 PM
Turner Christopher DurantChief Medical OfficerJun 05 '23Option Exercise6.8910,23570,51924,748Jun 07 04:50 PM
Noci DarleneChief Development OfficerJun 05 '23Option Exercise1.08600648600Jun 07 04:46 PM
Turner Christopher DurantChief Medical OfficerJun 05 '23Sale44.8610,235459,14214,513Jun 07 04:50 PM
Noci DarleneChief Development OfficerJun 05 '23Sale45.0060027,0000Jun 07 04:46 PM
Noci DarleneChief Development OfficerJun 01 '23Option Exercise1.083,0003,2403,000Jun 02 04:45 PM
Noci DarleneChief Development OfficerJun 01 '23Sale42.643,000127,9210Jun 02 04:45 PM
Miller Deborah AnnChief Legal OfficerMay 15 '23Option Exercise6.892,00013,7802,000May 17 04:44 PM
Miller Deborah AnnChief Legal OfficerMay 15 '23Sale40.742,00081,4890May 17 04:44 PM
Miller Deborah AnnChief Legal OfficerMay 09 '23Option Exercise6.891,3329,1771,332May 09 05:11 PM
Miller Deborah AnnChief Legal OfficerMay 09 '23Sale39.631,33252,7870May 09 05:11 PM
Miller Deborah AnnChief Legal OfficerMay 05 '23Option Exercise6.892,80019,2922,800May 09 05:11 PM
Miller Deborah AnnChief Legal OfficerMay 05 '23Sale39.642,800110,9920May 09 05:11 PM
Miller Deborah AnnChief Legal OfficerMay 01 '23Option Exercise6.899006,201900May 03 04:38 PM
Noci DarleneChief Development OfficerMay 01 '23Option Exercise1.083,0003,2403,000May 03 04:41 PM
Noci DarleneChief Development OfficerMay 01 '23Sale38.603,000115,7870May 03 04:41 PM
Miller Deborah AnnChief Legal OfficerMay 01 '23Sale39.6190035,6490May 03 04:38 PM
Miller Deborah AnnChief Legal OfficerApr 17 '23Option Exercise6.892,00013,7802,000Apr 19 04:46 PM
Miller Deborah AnnChief Legal OfficerApr 17 '23Sale30.102,00060,1980Apr 19 04:46 PM
Noci DarleneChief Development OfficerApr 03 '23Option Exercise1.083,0003,2403,000Apr 05 04:40 PM
Noci DarleneChief Development OfficerApr 03 '23Sale26.593,00079,7650Apr 05 04:40 PM